Magle Chemoswed Holding AB (publ) 52X.F Stock
Magle Chemoswed Holding AB (publ) Price Chart
Magle Chemoswed Holding AB (publ) 52X.F Financial and Trading Overview
Magle Chemoswed Holding AB (publ) stock price | 2.56 EUR |
Previous Close | 2.74 EUR |
Open | 2.78 EUR |
Bid | 2.76 EUR x N/A |
Ask | 2.86 EUR x N/A |
Day's Range | 2.78 - 2.78 EUR |
52 Week Range | 1.84 - 3.08 EUR |
Volume | 41 EUR |
Avg. Volume | 0 EUR |
Market Cap | 30.02M EUR |
Beta (5Y Monthly) | 0.594495 |
PE Ratio (TTM) | 46.333332 |
EPS (TTM) | 0.1 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
52X.F Valuation Measures
Enterprise Value | 29.59M EUR |
Trailing P/E | 46.333332 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 0.24489076 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | N/A |
Trading Information
Magle Chemoswed Holding AB (publ) Stock Price History
Beta (5Y Monthly) | 0.594495 |
52-Week Change | 48.42% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3.08 EUR |
52 Week Low | 1.84 EUR |
50-Day Moving Average | 2.7 EUR |
200-Day Moving Average | 2.44 EUR |
52X.F Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 10.8M |
Float | 10.63M |
Short Ratio | N/A |
% Held by Insiders | 78.60% |
% Held by Institutions | 0% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 6.17% |
Operating Margin (ttm) | 0% |
Gross Margin | 90.81% |
EBITDA Margin | 17.10% |
Management Effectiveness
Return on Assets (ttm) | 3.72% |
Return on Equity (ttm) | 6.40% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | 31.50% |
Gross Profit (ttm) | 134.01M EUR |
EBITDA | N/A |
Net Income Avi to Common (ttm) | N/A |
Diluted EPS (ttm) | 0.06 |
Quarterly Earnings Growth (yoy) | 38.29% |
Balance Sheet
Total Cash (mrq) | N/A |
Total Cash Per Share (mrq) | N/A |
Total Debt (mrq) | N/A |
Total Debt/Equity (mrq) | 36.35 EUR |
Current Ratio (mrq) | 1.278 |
Book Value Per Share (mrq) | 11.352 |
Cash Flow Statement
Operating Cash Flow (ttm) | N/A |
Levered Free Cash Flow (ttm) | N/A |
Profile of Magle Chemoswed Holding AB (publ)
Country | Germany |
State | N/A |
City | Malmö |
Address | Agneslundsvägen 27 |
ZIP | 212 15 |
Phone | 46 40 38 33 00 |
Website | https://www.maglechemoswed.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 75 |
Magle Chemoswed Holding AB (publ) engages in the research, development, and manufacturing in the areas of pharmaceutical chemistry and pharmaceutical technology in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); and research, development, and production of products in the areas of wound care and diagnostics with a focus on products based on degradable starch microspheres. Its APIs include Warfarin sodium products that are used as anticoagulants for multiple indications; Melperone hydrochloride, which is an antipsychotic agent; Isradipine, a calcium channel blocker used to treat hypertension; Amantadine sulfate that is used in the treatment of central nervous system disorders; and Benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers medical devices for applications in the areas of advanced wound care, surgical and diagnostics, and drug delivery comprising EmboCept S, a microsphere based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company's unique microsphere technology; SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures; and EmboCept M, a device for use in the treatment of benign prostatic hyperplasia. It serves companies in the pharmaceutical and medical device industry on a contract basis. The company was founded in 1944 and is headquartered in Malmö, Sweden. Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB.
Q&A For Magle Chemoswed Holding AB (publ) Stock
What is a current 52X.F stock price?
Magle Chemoswed Holding AB (publ) 52X.F stock price today per share is 2.56 EUR.
How to purchase Magle Chemoswed Holding AB (publ) stock?
You can buy 52X.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Magle Chemoswed Holding AB (publ)?
The stock symbol or ticker of Magle Chemoswed Holding AB (publ) is 52X.F.
Which industry does the Magle Chemoswed Holding AB (publ) company belong to?
The Magle Chemoswed Holding AB (publ) industry is Biotechnology.
How many shares does Magle Chemoswed Holding AB (publ) have in circulation?
The max supply of Magle Chemoswed Holding AB (publ) shares is 11.42M.
What is Magle Chemoswed Holding AB (publ) Price to Earnings Ratio (PE Ratio)?
Magle Chemoswed Holding AB (publ) PE Ratio is 25.59999800 now.
What was Magle Chemoswed Holding AB (publ) earnings per share over the trailing 12 months (TTM)?
Magle Chemoswed Holding AB (publ) EPS is 0.1 EUR over the trailing 12 months.
Which sector does the Magle Chemoswed Holding AB (publ) company belong to?
The Magle Chemoswed Holding AB (publ) sector is Healthcare.